European journal of nuclear medicine and molecular imaging
Journal
Overview
publication venue for
-
Correction to: [89Zr]Zr‑huJ591 immuno‑PET targeting PSMA in IDH mutant anaplastic oligodendroglioma.
2022
-
Surgical radioguidance with beta-emitting radionuclides; challenges and possibilities: A position paper by the EANM.
2024
-
Quantitative analysis of myocardial blood flow in surgically revascularized and not revascularized myocardial segments. A pilot PET study.
2023
-
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT).
2023
-
Low-count whole-body PET/MRI restoration: an evaluation of dose reduction spectrum and five state-of-the-art artificial intelligence models.
2023
-
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.
2023
-
The potential of a medium-cost long axial FOV PET system for nuclear medicine departments.
2022
-
Carbonic anhydrase IX stratifies patient prognosis and identifies nodal status in animal models of nasopharyngeal carcinoma using a targeted imaging strategy..
49.
2022
-
[89Zr]Zr-huJ591 immuno-PET targeting PSMA in IDH mutant anaplastic oligodendroglioma..
49.
2021
-
Prognostic value of [18F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapies.
2021
-
Artificial intelligence enables whole-body positron emission tomography scans with minimal radiation exposure..
48.
2021
-
A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals..
48.
2021
-
Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [68Ga]Ga-PSMA-11 PET/MRI..
48.
2020
-
Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer..
48.
2020
-
IntraOmmaya compartmental radioimmunotherapy using 131I-omburtamab-pharmacokinetic modeling to optimize therapeutic index..
48.
2020
-
Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy..
47.
2020
-
18F-Fluorocholine PET uptake correlates with pathologic evidence of recurrent tumor after stereotactic radiosurgery for brain metastases..
47.
2019
-
Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks..
47.
2019
-
Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy..
46.
2019
-
A multiparametric [18F]FDG PET/MRI diagnostic model including imaging biomarkers of the tumor and contralateral healthy breast tissue aids breast cancer diagnosis..
46.
2019
-
Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer..
46.
2018
-
Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy..
46.
2018
-
Biodistribution and radiation dose estimates for 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors..
46.
2018
-
Quantitative evaluation of tau PET tracers 18F-THK5351 and 18F-AV-1451 in Alzheimer's disease with standardized uptake value peak-alignment (SUVP) normalization..
45.
2018
-
Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors..
45.
2018
-
Tumour functional sphericity from PET images: prognostic value in NSCLC and impact of delineation method..
45.
2017
-
68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy - diagnostic performance and impact on therapeutic decision-making..
45.
2017
-
68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0..
44.
2017
-
Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer..
44.
2017
-
Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095..
44.
2017
-
Synthesis and pre-clinical evaluation of a new class of high-affinity 18F-labeled PSMA ligands for detection of prostate cancer by PET imaging..
44.
2016
-
(18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer..
43.
2016
-
Nuclear cardiology practice and associated radiation doses in Europe: results of the IAEA Nuclear Cardiology Protocols Study (INCAPS) for the 27 European countries..
43.
2015
-
Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates..
43.
2015
-
PET-based compartmental modeling of (124)I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer..
42.
2015
-
Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype..
42.
2015
-
Reduced retention of Pittsburgh compound B in white matter lesions..
42.
2014
-
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer..
41.
2014
-
18F-FDG PET of the hands with a dedicated high-resolution PEM system (arthro-PET): correlation with PET/CT, radiography and clinical parameters..
41.
2014
-
Performance of intra-procedural 18-fluorodeoxyglucose PET/CT-guided biopsies for lesions suspected of malignancy but poorly visualized with other modalities..
41.
2014
-
Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma..
41.
2014
-
Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy..
41.
2014
-
Synthesis and evaluation of 18F-labeled benzylguanidine analogs for targeting the human norepinephrine transporter..
41.
2013
-
Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer..
40.
2013
-
The impact of systemic chemotherapy on testicular FDG activity in young men with Hodgkin's lymphoma..
40.
2013
-
Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid..
38.
2010
-
Detection of hypoxia in microscopic tumors using 131I-labeled iodo-azomycin galactopyranoside (131I-IAZGP) digital autoradiography..
37.
2009
-
PET imaging of HSV1-tk mutants with acquired specificity toward pyrimidine- and acycloguanosine-based radiotracers..
36.
2009
-
Chronic thyroiditis in patients with advanced breast carcinoma: metabolic and morphologic changes on PET-CT..
36.
2009
-
FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease..
36.
2009
-
Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease..
35.
2008
-
Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30..
35.
2008
-
Tumor hypoxia imaging in orthotopic liver tumors and peritoneal metastasis: a comparative study featuring dynamic 18F-MISO and 124I-IAZG PET in the same study cohort..
35.
2007
-
Quantitation, regional vulnerability, and kinetic modeling of brain glucose metabolism in mild Alzheimer's disease..
34.
2007
-
Quantification of Parkinson's disease-related network expression with ECD SPECT..
34.
2006
-
Human radiation dosimetry of [11C]MeAIB, a new tracer for imaging of system A amino acid transport..
33.
2006
-
[131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity..
33.
2006
-
Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer's disease using FDG-PET..
33.
2005
-
Respiration artifacts in whole-body (18)F-FDG PET/CT studies with combined PET/CT tomographs employing spiral CT technology with 1 to 16 detector rows..
32.
2005
-
Dosimetry of 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET..
32.
2005
-
A preclinical model for noninvasive imaging of hypoxia-induced gene expression; comparison with an exogenous marker of tumor hypoxia..
31.
2004
-
Brain perfusion abnormalities in patients with euthyroid autoimmune thyroiditis..
31.
2004
-
Proliferation-dependent changes in amino acid transport and glucose metabolism in glioma cell lines..
31.
2004
-
A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging..
31.
2004
-
Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning..
31.
2003
-
[Tc(CO)(3)](+) chemistry: a promising new concept for SPECT? Against..
30.
2003
-
In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM..
30.
2003
-
Imaging of dihydrofolate reductase fusion gene expression in xenografts of human liver metastases of colorectal cancer in living rats..
30.
2003
-
Prognostic value of [18F]FDG-PET imaging in small cell lung cancer..
30.
2002
-
Comparison of SUV and Patlak slope for monitoring of cancer therapy using serial PET scans..
30.
2002
-
Whole-body skeletal imaging in mice utilizing microPET: optimization of reproducibility and applications in animal models of bone disease..
29.
2002
-
Amino acid uptake in the skeletal muscle measured using [11C]methylaminoisobutyrate (MEAIB) and PET..
29.
2002
-
Standardized uptake value in pediatric patients: an investigation to determine the optimum measurement parameter..
29.
2001
-
PSMA PET/CT cost-effectiveness analysis in the USA: a response to a published commentary.
2023
-
Toward individualized dosimetry for radiopharmaceutical therapy in day-to-day clinical practice of nuclear oncology: overcoming heterogeneity of radiation-absorbed dose to tumor and critical organs.
2023
-
Is nano too big?.
41.
2014
-
PSMA as a target for radiolabelled small molecules..
40.
2013
-
Doctor, what does my future hold? The prognostic value of FDG-PET in solid tumours.
2010
-
Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.
2005
-
PET/CT: a new imaging technology in nuclear medicine.
2003
-
Current clinical applications of Cerenkov luminescence for intraoperative molecular imaging.
2024
-
Dynamic whole-body PET imaging: principles, potentials and applications.
2018
-
From PET detectors to PET scanners.
2003
Identity
ISO Abbreviation
-
Eur J Nucl Med Mol Imaging
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)